The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00197782

Enrollment

Unknown

Registered

2005-09-20

Start date

2003-04-30

Completion date

2005-12-31

Last updated

2018-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haemophilus Influenzae Type b

Brief summary

To measure the magnitude and persistence of the antibody response to a booster dose of Hib conjugate vaccine given between 9 months and 4 years of age to UK children who had completed primary immunisation with 3 doses of Hib vaccine given at 2/3/4 months of age either as a combined D/T/wholecellpertussis/Hib or D/T/acellularpertussis/Hib vaccine.

Interventions

BIOLOGICALHib conjugate vaccine

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

9 Months to 4 Years

Healthy volunteers

Yes

Inclusion criteria

* Written informed consent from parent or legal guardian of the infant or child * Age \>= 9 months and \<4 years at recruitment * Eligible to receive a single dose of Hib vaccine as per the UK schedule * Receipt of three doses of Hib vaccine in infancy

Exclusion criteria

* History of Hib infection * History of severe local reaction that can be confidently related to a prior Hib immunisation * Deferral of vaccination if acute illness and/or temperature \>38C on day of vaccination

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026